ClinicalTrials.gg
CompletedNCT00692341Updated Apr 11, 2012Results posted

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

A Phase 1 interventional study of AG-013736 and AG-013736 in Hepatic Insufficiency, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-11.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.

Enrollment
30th of 48
24 · median 28
Started
2008
with 2 others
Phase 1
42 of 52
3 open now
Registered
7th of 52
by date
Lead sponsor
5 of 52
Pfizer

Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 30th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2008, is one of 42 in phase 1, and was the 7th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Hepatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

Keywords

  • hepatic impairment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of reduced hepatic function ( Classification A or B)
  • of 18-32 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History of febrile illness within 5 days prior to first dose
  • Any condition possibly affecting drug absorption (e.g. gastrectomy)
  • Positive urine drug screen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Hepatic Function - Mild Impairment

    Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)

    Drug: AG-013736

  • Experimental
    Hepatic Function - Moderate Impairment

    Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)

    Drug: AG-013736

  • Experimental
    Hepatic Function - Normal

    Group 1 1) subjects with normal hepatic function

    Drug: AG-013736

Interventions

  • Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

  • Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

  • Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hours (hrs) post-dose

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  3. Plasma Elimination Half-life (t1/2)

    Plasma elimination half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  4. Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  5. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the oral bioavailability.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  6. Fraction of Unbound Drug (fu)

    Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  7. Unbound Apparent Oral Clearance (CLu/F)

    Clearance of an unbound drug is a measure of the rate at which an unbound drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  8. Unbound Apparent Volume of Distribution (Vzu/F)

    Volume of distribution of unbound drug is defined as the theoretical volume in which the total amount of unbound drug would need to be uniformly distributed to produce the desired plasma concentration of unbound drug. Unbound apparent volume of distribution after oral dose (Vzu/F) is influenced by the oral bioavailability.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  9. Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]

    AUC (0 - ∞)u = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) for unbound drug. It is obtained from AUCu (0 - t) plus AUCu (t - ∞).

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  10. Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

  11. Unbound Maximum Observed Plasma Concentration (Cmaxu)

    Cmaxu is the highest measured unbound plasma concentration during the dosing interval.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose

07

Results

Posted Mar 27, 2012

Participant flow

Participant flow — Overall Study
MilestoneAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Started888
Completed888
Not completed000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hours (hrs) post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Maximum Observed Plasma Concentration (Cmax)30.43 ± 50.0026.96 ± 127.0038.85 ± 50.00
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 88.61 · 90% CI 49.20 to 159.56
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 127.67 · 90% CI 70.90 to 229.91
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
ng*hr/mLAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]155.68 ± 63.00121.96 ± 167.00303.96 ± 44.00
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 78.34 · 90% CI 39.92 to 153.75
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 195.25 · 90% CI 99.49 to 383.18
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)148.43 ± 69.00115.98 ± 180.00295.23 ± 44.00
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 78.14 · 90% CI 38.68 to 157.82
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 198.90 · 90% CI 98.47 to 401.74
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Time to Reach Maximum Observed Plasma Concentration (Tmax)3.50 (2.00 to 4.00)2.75 (1.00 to 4.00)4.00 (1.50 to 4.00)
SecondaryPlasma Elimination Half-life (t1/2)

Plasma elimination half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Mean · hr
Plasma Elimination Half-life (t1/2)
hrAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Plasma Elimination Half-life (t1/2)4.74 ± 3.773.61 ± 3.027.12 ± 6.49
SecondaryApparent Oral Clearance (CL/F)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · mL/min
Apparent Oral Clearance (CL/F)
mL/minAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Apparent Oral Clearance (CL/F)535.3 ± 63.0683.3 ± 167.0274.2 ± 44.0
SecondaryApparent Volume of Distribution (Vz/F)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the oral bioavailability.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · Liter (L)
Apparent Volume of Distribution (Vz/F)
Liter (L)Axitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Apparent Volume of Distribution (Vz/F)166.43 ± 52.00162.65 ± 87.00127.68 ± 67.00
SecondaryFraction of Unbound Drug (fu)

Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · Ratio
Fraction of Unbound Drug (fu)
RatioAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Fraction of Unbound Drug (fu)0.004 ± 25.0000.003 ± 50.0000.004 ± 134.000
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 73.78 · 90% CI 37.40 to 145.56
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 100.86 · 90% CI 55.58 to 183.02
SecondaryUnbound Apparent Oral Clearance (CLu/F)

Clearance of an unbound drug is a measure of the rate at which an unbound drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · mL/min
Unbound Apparent Oral Clearance (CLu/F)
mL/minAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Unbound Apparent Oral Clearance (CLu/F)132218.6 ± 56.0120883.5 ± 82.067143.1 ± 109.0
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 91.43 · 90% CI 44.75 to 186.79
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 50.78 · 90% CI 27.14 to 95.03
SecondaryUnbound Apparent Volume of Distribution (Vzu/F)

Volume of distribution of unbound drug is defined as the theoretical volume in which the total amount of unbound drug would need to be uniformly distributed to produce the desired plasma concentration of unbound drug. Unbound apparent volume of distribution after oral dose (Vzu/F) is influenced by the oral bioavailability.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · L
Unbound Apparent Volume of Distribution (Vzu/F)
LAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Unbound Apparent Volume of Distribution (Vzu/F)41108.6 ± 57.042378.3 ± 40.031268.8 ± 121.0
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 103.09 · 90% CI 51.53 to 206.22
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 76.06 · 90% CI 41.41 to 139.73
SecondaryUnbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]

AUC (0 - ∞)u = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞) for unbound drug. It is obtained from AUCu (0 - t) plus AUCu (t - ∞).

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]
ng*hr/mLAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]0.63 ± 56.000.69 ± 82.001.24 ± 109.00
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 109.38 · 90% CI 53.54 to 223.47
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 196.92 · 90% CI 105.23 to 368.49
SecondaryUnbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)
ng*hr/mLAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)0.60 ± 61.000.67 ± 81.001.21 ± 106.00
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Adjusted ratio of geometric means: 111.65 · 90% CI 54.35 to 229.37
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 200.60 · 90% CI 106.68 to 377.20
SecondaryUnbound Maximum Observed Plasma Concentration (Cmaxu)

Cmaxu is the highest measured unbound plasma concentration during the dosing interval.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 16, 24, 36, 48, 96 and 144 hrs post-dose
Reported as:
Geometric mean · ng/mL
Unbound Maximum Observed Plasma Concentration (Cmaxu)
ng/mLAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
Unbound Maximum Observed Plasma Concentration (Cmaxu)0.12 ± 46.000.13 ± 47.000.16 ± 97.00
Statistical analysis
  • Axitinib : Normal Hepatic Function vs Axitinib : Mild Hepatic Impairment · Ratio of adjusted geometric means: 106.82 · 90% CI 58.22 to 195.99
  • Axitinib : Normal Hepatic Function vs Axitinib : Moderate Hepatic Impairment · Ratio of adjusted geometric means: 128.76 · 90% CI 75.62 to 219.25

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib : Normal Hepatic Function—0/8 (0%)3/8 (37.5%)
Axitinib : Mild Hepatic Impairment—0/8 (0%)0/8 (0%)
Axitinib : Moderate Hepatic Impairment—0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventAxitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic Impairment
LethargyNervous system disorders3/80/80/8
HeadacheNervous system disorders1/80/80/8

Baseline characteristics

Age Continuous
Age Continuous(years)Axitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic ImpairmentTotal
Mean47.4 ± 5.252.5 ± 5.654.3 ± 4.751.4 ± 5.8
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib : Normal Hepatic FunctionAxitinib : Mild Hepatic ImpairmentAxitinib : Moderate Hepatic ImpairmentTotal
Female1124
Male77620
08

Study locations

2 sites
  • Pfizer Investigational Site
    Miami, Florida 33169, United States
  • Pfizer Investigational Site
    Orlando, Florida 32809, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2008
First posted
Jun 6, 2008
Start
May 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Mar 27, 2012
Last update
Apr 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00692341
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 6, 2008
Start date
May 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Mar 27, 2012
Last update
Apr 11, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion